Across TCGA pan-cancer cohorts, CRELD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRELD2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CRELD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRELD2 expression acts as an unfavorable survival marker.

LIHC, STAD, and BRCA are the cancer types where CRELD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.095	0.546	<.001	24	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
BRCA	DFS	Median	All	0.662	0.904	.007	10	view →
SARC	DFS	Median	All	0.037	0.632	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CRELD2 tumor-vs-normal RNA expression · all CRELD2 data types